30 results on '"Emmanuel Dudoignon"'
Search Results
2. Indice de perfusion : principes physiques, signification physiologique et implications cliniques en anesthésie et réanimation
- Author
-
Maxime Coutrot, Colleen Breslin, Emmanuel Dudoignon, and François Dépret
- Subjects
Anesthesiology and Pain Medicine - Published
- 2022
3. Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre study
- Author
-
Dirk van Lier, Benjamin Deniau, Karine Santos, Oliver Hartmann, Emmanuel Dudoignon, François Depret, Benoit Plaud, Pierre-Francois Laterre, Alexandre Mebazaa, and Peter Pickkers
- Subjects
Pulmonary and Respiratory Medicine ,All institutes and research themes of the Radboud University Medical Center ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] - Abstract
IntroductionDipeptidyl peptidase-3 (DPP3) is a protease involved in the degradation of several cardiovascular mediators. Adrenomedullin (bio-ADM) is a peptide essential for regulation of endothelial barrier function. In different shock-pathologies, both biomarkers are associated with disease severity, organ dysfunction and mortality. Associations with outcome in critically ill COVID-19 patients are unknown. The objectives of the present study were to investigate associations of bio-ADM and “circulating DPP3” (cDPP3) with short-term outcome in critically ill COVID-19 patients (n=80).MethodsA multicentre prospective cohort study was performed. The primary end-point was 28-day mortality. Secondary end-points included different severities of acute kidney injury (AKI).ResultscDPP3 levels were mainly associated with 28-day mortality; Area under the receiver operating characteristics (AUROCs) of 0.69 (0.56–0.82, p=0.023), 0.77 (0.64–0.90, pConclusionscDPP3 and bio-ADM responses were associated with short-term mortality and AKI in critically ill COVID-19 patients, respectively. These findings suggest that treatment with specific antibodies modulating cDPP3 or bio-ADM-related pathways may improve outcome of COVID-19.
- Published
- 2023
4. First Patient-to-Patient Intrahospital Transmission of Clade I Candida auris in France Revealed after a Two-Month Incubation Period
- Author
-
Alexandre Alanio, Hannah Marie Snell, Camille Cordier, Marie Desnos-Olivier, Sarah Dellière, Nesrine Aissaoui, Aude Sturny-Leclère, Elodie Da Silva, Cyril Eblé, Martine Rouveau, Micheline Thégat, Widad Zebiche, Matthieu Lafaurie, Blandine Denis, Sophie Touratier, Mourad Benyamina, Emmanuel Dudoignon, Samia Hamane, Christina A. Cuomo, and François Dépret
- Subjects
Microbiology (medical) ,Antifungal Agents ,Whole Genome Sequencing ,General Immunology and Microbiology ,Ecology ,Physiology ,Candidiasis ,Microbial Sensitivity Tests ,Cell Biology ,Candida auris ,Infectious Disease Incubation Period ,Infectious Diseases ,Genetics ,Humans ,Candida - Abstract
While large outbreaks of C. auris in hospital settings have been described, few clear cases of direct transmission have been documented. We here investigated the transmission of C. auris clade I between two patients with a 41- to 61-day delay between exposure and the development of colonization. This may lead to changes in the recommendations concerning treatment of C. auris cases, as an incubation period of this length is one of the first to be reported.
- Published
- 2022
5. Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study
- Author
-
Jan A Staessen, Ralph Wendt, Yu-Ling Yu, Sven Kalbitz, Lutgarde Thijs, Justyna Siwy, Julia Raad, Jochen Metzger, Barbara Neuhaus, Armin Papkalla, Heiko von der Leyen, Alexandre Mebazaa, Emmanuel Dudoignon, Goce Spasovski, Mimoza Milenkova, Aleksandra Canevska-Taneska, Mercedes Salgueira Lazo, Mina Psichogiou, Marek W Rajzer, Łukasz Fuławka, Magdalena Dzitkowska-Zabielska, Guenter Weiss, Torsten Feldt, Miriam Stegemann, Johan Normark, Alexander Zoufaly, Stefan Schmiedel, Michael Seilmaier, Benedikt Rumpf, Mirosław Banasik, Magdalena Krajewska, Lorenzo Catanese, Harald D Rupprecht, Beata Czerwieńska, Björn Peters, Åsa Nilsson, Katja Rothfuss, Christoph Lübbert, Harald Mischak, Joachim Beige, Lukasz Fulawka, Harald Rupprecht, Beata Czerwienska, Jörg Ermisch, Nils Kellner, Lydia Peruth-Stutzmann, Stefanie Schroth, Jonathan Schmidt, Ulrike Schmidt, Daniel Breuer, Fariza Abeud, Marie-Celine Fournier, Badr Louadah, Rocio Molas, Fraile Loreto Rojas, Fabiola Alonso García, Isabel Garcia Sánchez, Ioana Cezara Hrom, Andrzej Więczek., Matthias Schwab, Kei K Asayama, Tine W Hansen, Gladys E Maestre, Dimitrios Basoulis, Georgios Karamanakos., Pawel Lis, Agnieszka Olszanecka, Rosa Bellmann-Weiler, Lucas Lanser, Alicia Edin, Matthias NE Forsell, Bernd Stegmayr, Björn-Erik Ole Jensen, Hans-Martin Orth, Sylke Borstel, Agata Mikolajewska, Manfred Hecking, Lukas Schmölz, Michał Hoffmann, Krzysztof Narkiewicz, Agnieszka Matera-Witkiewicz, Justyna Zachciał, Monika Litwin, and Patrycja Marciniak
- Subjects
Adult ,Proteomics ,SARS-CoV-2 ,Medicine (miscellaneous) ,COVID-19 ,Public Health, Global Health, Social Medicine and Epidemiology ,Health Informatics ,Pilot Projects ,Cohort Studies ,Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi ,Health Information Management ,Urologi och njurmedicin ,Disease Progression ,Urology and Nephrology ,Humans ,Decision Sciences (miscellaneous) ,Prospective Studies ,Biomarkers - Abstract
BACKGROUND: The SARS-CoV-2 pandemic is a worldwide challenge. The CRIT-CoV-U pilot study generated a urinary proteomic biomarker consisting of 50 peptides (COV50), which predicted death and disease progression from SARS-CoV-2. After the interim analysis presented for the German Government, here, we aimed to analyse the full dataset to consolidate the findings and propose potential clinical applications of this biomarker. METHODS: CRIT-CoV-U was a prospective multicentre cohort study. In eight European countries (Austria, France, Germany, Greece, North Macedonia, Poland, Spain, and Sweden), 1012 adults with PCR-confirmed COVID-19 were followed up for death and progression along the 8-point WHO scale. Capillary electrophoresis coupled with mass spectrometry was used for urinary proteomic profiling. Statistical methods included logistic regression and receiver operating characteristic curve analysis with a comparison of the area under curve (AUC) between nested models. Hospitalisation costs were derived from the care facility corresponding with the Markov chain probability of reaching WHO scores ranging from 3 to 8 and flat-rate hospitalisation costs adjusted for the gross per capita domestic product of each country. FINDINGS: From June 30 to Nov 19, 2020, 228 participants were recruited, and from April 30, 2020, to April 14, 2021, 784 participants were recruited, resulting in a total of 1012 participants. The entry WHO scores were 1-3 in 445 (44%) participants, 4-5 in 529 (52%) participants, and 6 in 38 (4%) participants; and of all participants, 119 died and 271 had disease progression. The odds ratio (OR) associated with COV50 in all 1012 participants for death was 2·44 (95% CI 2·05-2·92) unadjusted and 1·67 (1·34-2·07) when adjusted for sex, age, BMI, comorbidities, and baseline WHO score; and for disease progression, the OR was 1·79 (1·60-2·01) when unadjusted and 1·63 (1·41-1·91) when adjusted (p
- Published
- 2022
6. Multiplex bacterial PCR for antibiotic stewardship in pneumonia
- Author
-
Emmanuel Dudoignon, Maxime Coutrot, François Camelena, Marc Leone, and François Dépret
- Subjects
Pulmonary and Respiratory Medicine ,Community-Acquired Infections ,Antimicrobial Stewardship ,Humans ,Pneumonia ,Multiplex Polymerase Chain Reaction ,Anti-Bacterial Agents - Published
- 2022
7. What's new in antibiotic stewardship for pneumonia in ICU?
- Author
-
François Dépret, Marc Leone, Francois Camelena, and Emmanuel DUDOIGNON
- Subjects
Antimicrobial Stewardship ,Intensive Care Units ,Anesthesiology and Pain Medicine ,Humans ,General Medicine ,Pneumonia ,Critical Care and Intensive Care Medicine ,Anti-Bacterial Agents - Published
- 2022
8. Omicron Variant in the Critical Care Units of the Paris Metropolitan Area: The Reality Research Group
- Author
-
Antoine Vieillard-Baron, Rémi Flicoteaux, Maud Salmona, Appoline Chariot, Bertrand De Maupeou D’Ableiges, Michael Darmon, Frédéric Batteux, Djillali Annane, Soufia Ayed, Elie Azoulay, Raphael Bellaiche, Sadek Beloucif, Enora Berti, Astrid Bertier, Sébastien Besset, Marlène Bret, Alain Cariou, Christophe Carpentier, Oussama Chaouch, Cyril Charron, Julien Charpentier, Cherifa Cheurfa, Bernard Cholley, Benjamin Chousterman, Sébastien Clerc, Yves Cohen, Alain Combes, Jean-Michel Constantin, Charles Damoisel, Vincent Degos, Sophie Demeret, Etienne De Montmollin, Alexandre Demoule, Francois Depret, Jean-Luc Diehl, Michel Djibré, Chung-Hi Do, Emmanuel Dudoignon, Jacques Duranteau, Muriel Fartoukh, Fabienne Fieux, Etienne Gayat, Mael Gennequin, Bertrand Guidet, Christophe Gutton, Sophie Hamada, Nicholas Heming, Romain Jouffroy, Hawa Keita-Meyer, Olivier Langeron, Brice Lortat-Jacob, Jonathan Marey, Alexandre Mebazaa, Bruno Megarbane, Armand Mekontso-Dessap, Jean-Paul Mira, Julie Molle, Nicolas Mongardon, Philippe Montravers, Capucine Morelot-Panzini, Safaa Nemlaghi, Bao-long Nguyen, Antoine Parrot, Romain Pasqualotto, Nicolas Peron, Lucile Picard, Marc Pineton de Chambrun, Benjamin Planquette, Benoit Plaud, Stéphanie Pons, Christophe Quesnel, Jean-Herlé Raphalen, Keyvan Razazi, Jean-Damien Ricard, Anne Roche, Benjamin Rohaut, Damien Roux, Laurent Savale, Jennifer Sobotka, Jean-Louis Teboul, Jean-François Timsit, Guillaume Voiriot, Emmanuel Weiss, Lucille Wildenberg, Elie Zogheib, and Bruno Riou
- Subjects
Pulmonary and Respiratory Medicine ,Intensive Care Units ,Paris ,Critical Care ,Humans ,Critical Care and Intensive Care Medicine - Published
- 2022
9. Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials
- Author
-
Mohamed Aziz Daghmouri, Emmanuel Dudoignon, Mohamed Ali Chaouch, Josefine Baekgaard, Adrien Bougle, Marc Leone, Benjamin Deniau, and François Depret
- Subjects
General Medicine - Published
- 2023
10. Reply to: 'Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered'
- Author
-
Vincent Mallet, Kilian Bock, Mourad Dellagi, Marion Tano, Virginie Siorat, Nathanaël Beeker, Pascal Paubel, Paul Doumbe Mandengue, Nicolas Dufour, Torsten Voigtländer, Jean-Damien Ricard, Pierre Isnard, Vincent Frochot, Emmanuel Letavernier, Lucile Moga, Amandine Landrieux, Pierre-Emmanuel Rautou, Nathalie Pons-Kerjean, Anaïs Vallet-Pichard, Clémence Hollande, Hélène Fontaine, Laurent Chouchana, Coralie Gernez, Carole Burger, Anne Scemla, Christian de Tymowski, François Depret, Emmanuel Dudoignon, Lionel Lamhaut, Rémi Flicoteau, Géraldine Rousseau, Jean-Paul Duong Van Huyen, Jean-Michel Correas, Heiner Wedemeyer, and Stanislas Pol
- Subjects
medicine.medical_specialty ,2019-20 coronavirus outbreak ,Hepatology ,Coronavirus disease 2019 (COVID-19) ,medicine.diagnostic_test ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine.disease ,Gastroenterology ,Cholestasis ,Internal medicine ,medicine ,Ketamine ,Bile Duct Diseases ,Liver function tests ,business ,medicine.drug - Published
- 2021
11. Prevalence of post-acute coronavirus disease 2019 symptoms twelve months after hospitalization in participants retained in follow-up: analyses stratified by gender from a large prospective cohort
- Author
-
Jade Ghosn, Delphine Bachelet, Marine Livrozet, Minerva Cervantes-Gonzalez, Julien Poissy, François Goehringer, Charlotte Salmon Gandonniere, Mylène Maillet, Firouzé Bani-Sadr, Guillaume Martin-Blondel, Pierre Tattevin, Odile Launay, Laure Surgers, Emmanuel Dudoignon, Geoffroy Liegeon, David Zucman, Cédric Joseph, Eric Senneville, Cécile Yelnik, Pierre-Marie Roger, Karine Faure, Marie Gousseff, André Cabié, Xavier Duval, Catherine Chirouze, and Cédric Laouénan
- Subjects
Microbiology (medical) ,Infectious Diseases ,General Medicine - Abstract
Persistent post-acute coronavirus disease 2019 (COVID-19) symptoms (PACSs) have been reported up to 6 months after hospital discharge. Herein we assessed the symptoms that persisted 12 months (M12) after admission for COVID-19 in the longitudinal prospective national French coronavirus disease cohort.Hospitalized patients with a confirmed virological diagnosis of COVID-19 were enrolled. Follow-up was planned until M12 after admission. Associations between persistence of ≥3 PACSs at M12 and clinical characteristics at admission were assessed through logistic regression according to gender.We focused on participants enrolled between 24 January 2020 and 15 July 2020, to allow M12 follow-up. The M12 data were available for 737 participants. Median age was 61 years, 475 (64%) were men and 242/647 (37%) were admitted to intensive care units during the acute phase. At M12, 27% (194/710) of the participants had ≥3 persistent PACS, mostly fatigue, dyspnoea and joint pain. Among those who had a professional occupation before the acute phase, 91 out of 339 (27%) were still on sick leave at M12. Presence of ≥3 persistent PACS was associated with female gender, both anxiety and depression, impaired health-related quality of life and Medical Muscle Research Council Scale57. Compared with men, women more often reported presence of ≥3 persistent PACSs (98/253, 39% vs. 96/457, 21%), depression and anxiety (18/152, 12% vs. 17/268, 6% and 33/156, 21% vs. 26/264, 10%, respectively), impaired physical health-related quality of life (76/141, 54% vs. 120/261, 46%). Women had less often returned to work than men (77/116, 66% vs. 171/223, 77%).One fourth of the individuals admitted to hospital for COVID-19 still had ≥3 persistent PACSs at M12 post-discharge. Women reported more often ≥3 persistent PACSs, suffered more from anxiety and depression and had less often returned to work than men.
- Published
- 2022
12. Combination of Mycological Criteria: a Better Surrogate to Identify COVID-19-Associated Pulmonary Aspergillosis Patients and Evaluate Prognosis?
- Author
-
Sarah Dellière, Emmanuel Dudoignon, Sébastian Voicu, Magalie Collet, Sofiane Fodil, Benoit Plaud, Benjamin Chousterman, Stéphane Bretagne, Elie Azoulay, Alexandre Mebazaa, François Dépret, Bruno Mégarbane, Alexandre Alanio, Mycologie moléculaire - Molecular Mycology, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Anesthésie-Réanimation [AP-HP Hôpitaux Saint-Louis Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Réanimation Médicale et Toxicologique [Hôpital Lariboisière], Optimisation thérapeutique en Neuropsychopharmacologie (OPTeN (UMR_S_1144 / U1144)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hopital Saint-Louis [AP-HP] (AP-HP), Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals (CNRMA), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, and Mégarbane, Bruno
- Subjects
Invasive Pulmonary Aspergillosis ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Microbiology (medical) ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,diagnosis ,COVID-19 ,Covid 19 ,Prognosis ,Sensitivity and Specificity ,[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Mannans ,[SDV.TOX] Life Sciences [q-bio]/Toxicology ,critical care ,Aspergillus ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.TOX]Life Sciences [q-bio]/Toxicology ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Humans ,[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,Pulmonary Aspergillosis ,Bronchoalveolar Lavage Fluid - Abstract
International audience; Diagnosis of coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) remains unclear especially in nonimmunocompromised patients. The aim of this study was to evaluate seven mycological criteria and their combination in a large homogenous cohort of patients. All successive patients (n = 176) hospitalized for COVID-19 requiring mechanical ventilation and who clinically worsened despite appropriate standard of care were included over a 1-year period. Direct examination, culture, Aspergillus quantitative PCR (Af-qPCR), and galactomannan testing were performed on all respiratory samples (n = 350). Serum galactomannan, β-d-glucan, and plasma Af-qPCR were also assessed. The criteria were analyzed alone or in combination in relation to mortality rate. Mortality was significantly different in patients with 0, ≤2, and ≥3 positive criteria (log rank test, P = 0.04) with death rate of 43.1, 58.1, and 76.4%, respectively. Direct examination, plasma qPCR, and serum galactomannan were associated with a 100% mortality rate. Bronchoalveolar lavage (BAL) galactomannan and positive respiratory sample culture were often found as isolated markers (28.1 and 34.1%) and poorly repeatable when a second sample was obtained. Aspergillus DNA was detected in 13.1% of samples (46 of 350) with significantly lower quantitative cycle (Cq) when associated with at least one other criterion (30.2 versus 35.8) (P < 0.001). A combination of markers and/or blood biomarkers and/or direct respiratory sample examination seems more likely to identify patients with CAPA. Af-qPCR may help identifying false-positive results of BAL galactomannan testing and culture on respiratory samples while quantifying fungal burden accurately.
- Published
- 2022
13. Early hypoalbuminemia is associated with 28-day mortality in severely burned patients: A retrospective cohort study
- Author
-
Maurice Mimoun, Maïté Chaussard, Alexandre Fratani, Christian de Tymowski, Haikel Oueslati, Alexandru Cupaciu, James Anstey, Lucie Guillemet, Mourad Benyamina, Alexandre Mebazaa, Matthieu Legrand, Simon Pallado, Nabilla Moreno, Maxime Coutrot, Marion Jully, Sabri Soussi, M. Chaouat, Emmanuel Dudoignon, and François Dépret
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Burn Units ,Context (language use) ,Critical Care and Intensive Care Medicine ,Post injury ,Gastroenterology ,Capillary Permeability ,Cohort Studies ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Albumins ,Sepsis ,Internal medicine ,medicine ,Humans ,Severe burn ,Hypoalbuminemia ,Mortality ,Serum Albumin ,Aged ,Retrospective Studies ,Respiratory Distress Syndrome ,Trauma Severity Indices ,business.industry ,Albumin ,030208 emergency & critical care medicine ,Retrospective cohort study ,Crystalloid Solutions ,General Medicine ,Acute Kidney Injury ,Length of Stay ,Middle Aged ,Prognosis ,medicine.disease ,Respiration, Artificial ,Renal Replacement Therapy ,Emergency Medicine ,Fluid Therapy ,Female ,Surgery ,Burns ,28 day mortality ,Multiple organ dysfunction syndrome ,business - Abstract
Hypoalbuminemia is a frequent condition in the first 24 h after a severe burn injury and is associated with worse outcomes.We investigated the relation between very early hypoalbuminemia (6 h after admission) and clinical outcome in a retrospective cohort admitted to our unit for severe burn injuries between 2012 and 2017.73 severely burned patients were included, with a delay of admission of 3 (2-4) h. In a context of early exogenous supply of albumin, admission and 4H Albuminemia (Alb4 h) were significantly lower in deceased patients (respectively, 34 (29-37) vs 27 (23-30) g/l; p = 0.009 and 27 (24-32) vs 21 (17-27) g/l; p = 0.022) whereas albuminemia ≥6 h were not. The best threshold value of Alb4 h to discriminate 28-day mortality was 23 g/l. Patients with an Alb4 h 23 g/l had a higher 28-day mortality than patients with an Alb4 h ≥ 23 g/l (42% vs 11%; p = 0.003); adjusted OR = 4.47 (95% CI 1.15-17.36); p = 0.03.In severely burned patients receiving early albumin supply, early hypoalbuminemia is associated with higher mortality whereas later albuminemia (≥6 h) is not. Exploration of whether early albumin infusion (8-12 h post injury) may alter clinical outcome is warranted.
- Published
- 2020
14. EPIDEMIOLOGICAL CHARACTERISTICS AND SEVERITY OF OMICRON VARIANT CASES IN THE APHP CRITICAL CARE UNITS
- Author
-
Antoine Vieillard-Baron, Rémi Flicoteaux, Maud Salmona, Djillali Annane, Soufia Ayed, Elie Azoulay, Raphael Bellaiche, Sadek Beloucif, Enora Berti, Astrid Bertier, Sébastien Besset, Marlène Bret, Alain Cariou, Christophe Carpentier, Oussama Chaouch, Appoline Chariot, Cyril Charron, Julien Charpentier, Cherifa Cheurfa, Bernard Cholley, Sébastien Clerc, Alain Combes, Benjamin Chousterman, Yves Cohen, Jean-Michel Constantin, Charles Damoisel, Michael Darmon, Vincent Degos, Bertrand De Maupeou D’Ableiges, Sophie Demeret, Etienne De Montmollin, Alexandre Demoule, Francois Depret, Jean-Luc Diehl, Michel Djibré, Chung-Hi Do, Emmanuel Dudoignon, Jacques Duranteau, Muriel Fartoukh, Fabienne Fieux, Etienne Gayat, Mael Gennequin, Bertrand Guidet, Christophe Gutton, Sophie Hamada, Nicholas Heming, Romain Jouffroy, Hawa Keita-Meyer, Olivier Langeron, Brice Lortat-Jacob, Jonathan Marey, Alexandre Mebazaa, Bruno Megarbane, Armand Mekontso-Dessap, Jean-Paul Mira, Julie Molle, Nicolas Mongardon, Philippe Montravers, Capucine Morelot-Panzini, Safaa Nemlaghi, Bao-long Nguyen, Antoine Parrot, Romain Pasqualotto, Nicolas Peron, Lucile Picard, Marc Pineton de Chambrun, Benjamin Planquette, Benoit Plaud, Stéphanie Pons, Christophe Quesnel, Jean-Herlé Raphalen, Keyvan Razazi, Jean-Damien Ricard, Anne Roche, Benjamin Rohaut, Damien Roux, Laurent Savale, Jennifer Sobotka, Jean-Louis Teboul, Jean-François Timsit, Guillaume Voiriot, Emmanuel Weiss, Lucille Wildenberg, Elie Zogheib, Bruno Riou, and Frédéric Batteux
- Abstract
ImportanceInformation about the severity of Omicron is scarce.ObjectiveTo report the respective risk of ICU admission in patients hospitalized with Delta and Omicron variants and to compare the characteristics and disease severity of critically ill patients infected with both variants according to vaccination status.DesignAnalysis from the APHP database, called Reality, prospectively recording the following information in consecutive patients admitted in the ICU for COVID-19: age, sex, immunosuppression, vaccination, pneumonia, need for invasive mechanical ventilation, time between symptom onset and ICU admission, and in-ICU mortality. Retrospective analysis on an administrative database, “Système d’Information pour le Suivi des Victimes” (SI-VIC), which lists hospitalized COVID-19 patients.Setting39 hospitals in the Paris area from APHP group.ParticipantsPatients hospitalized from December 1, 2021 to January 18, 2022 for COVID-19.Main outcomes and measuresRisk of ICU admission was evaluated in 3761 patients and Omicron cases were compared to Delta cases in the ICU in 888 consecutive patients.ResultsOn January 18, 45% of patients in the ICU and 63.8% of patients in conventional hospital units were infected with the Omicron variant (p < 0.001). The risk of ICU admission with Omicron was reduced by 64% than with Delta (9.3% versus 25.8% of cases, respectively, p < 0.001). In critically ill patients, 400 had the Delta variant, 229 the Omicron variant, 98 had an uninformative variant screening test and 161 did not have information on variant screening test. 747 patients (84.1%) were admitted for pneumonia. Compared to patients infected with Delta, Omicron patients were more vaccinated (pConclusion and relevanceCompared to the Delta variant, the Omicron variant is less likely to result in ICU admission and less likely to be associated with pneumonia. However, when patients with the Omicron variant are admitted for pneumonia, the severity seems similar to that of patients with the Delta variant, with more immunocompromised and vaccinated patients and no difference in adjusted in-ICU mortality. Further studies are needed to confirm our results.
- Published
- 2022
15. Predictive Performance and Clinical Application of COV50, A Urinary Proteomic Biomarker in Early COVID-19 Infection: A Cohort Study
- Author
-
Jan Staessen, Ralph Wendt, Yu-Ling Yu, Sven Kalbitz, Lutgarde Thijs, Justyna Siwy, Julia Raad, Jochen Metzger, Barbara Neuhaus, Armin Papkalla, Heiko von der Leyen, Alexandre Mebazaa, Emmanuel Dudoignon, Goce Spasovski, Mimoza Milenkova, Aleksandra Canevska-Tanevska, Mina Psichogiou, Marek W. Rajzer, Lukasz Fulawka, Magdalena Dzitkowska-Zabielska, Günter Weiss, Torsten Feldt, Miriam Songa Stegemann, Johan Normark, Alexander Zoufaly, Stefan Schmiedel, Michael Seilmaier, Benedikt Rumpf, Miroslaw Banasik, Magdalena Krajewska, Lorenzo Catanese, Harald Rupprecht, Beata Czerwienska, Björn Peters, Asa Nilsson, Katja Rothfuss, Christoph Lübbert, Harald Mischak, Joachim Beige, and CRIT-Cov-U Investigators
- Subjects
History ,Polymers and Plastics ,Business and International Management ,Industrial and Manufacturing Engineering - Published
- 2022
16. Epidemiological Characterisation of Omicron Variant Cases in the APHP Critical Care Units
- Author
-
Antoine Vieillard-Baron, Remi Flicoteaux, Maud Salmona, djillali annane, Soufia Ayed, Elie Azoulay, Raphael Bellaiche, Sadek Beloucif, Enora Berti, Astrid Bertier, Sebastien Besset, Marlène Bret, Alain Cariou, Christophe Carpentier, Oussama Chaouch, Cyril Charron, Julien Charpentier, Cherifa Cheurfa, Bernard Cholley, Sebastien Clerc, Alain Combes, Benjamin Chousterman, Yves Cohen, Jean Michel Constantin, Charles Damoisel, Michael Darmon, Vincent Degos, Bertrand De Maupeou D'Ableiges, Sophie Demeret, Etienne De Montmollin, Alexandre Demoule, François depret, Jean-Luc Diehl, Michel Djibré, Do Chung-Hi, Emmanuel Dudoignon, Jacques Duranteau, Muriel Fartoukh, Fabienne Fieux, Etienne Gayat, Mael Gennequin, Bertrand Guidet, Christophe Gutton, Sophie HAMADA, Nicholas Heming, Romain Jouffroy, Hawa Keita-Meyer, Olivier Langeron, Brice Lortat-Jacob, Jonathan Marey, Alexandre Mebazaa, Bruno Megarbane, Armand Mekontso Dessap, Jean-Paul Mira, Julie Molle, Philippe Montravers, Capucine Morelot-Panzini, Safaa Nemlaghi, Bao-long Nguyen, Antoine Parrot, Romain Pasqualotto, Nicolas Peron, Lucile Picard, marc Pineton de Chambrun, Benjamin Planquette, Benoit Plaud, Pons Stephanie, Christophe Quesnel, Jean-Herle Raphalen, Keyvan Razazi, Jean-Damien Ricard, Anne Roche, Benjamin Rohaut, Damien Roux, Laurent Savale, Jennifer Sobotka, Jean-Louis Teboul, Jean-Francois Timsit, Guillaume Voiriot, Emmanuel Weiss, Lucille Wildenberg, Elie Zogheib, Bruno Riou, and Frederic Batteux
- Published
- 2022
17. A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients
- Author
-
Jan A. Staessen, Emmanuel Dudoignon, Barbara Neuhaus, Lutgarde Thijs, Joachim Beige, K Rothfuss, Beata Czerwieńska, Åsa Nilsson, Alexandre Mebazaa, Jochen Metzger, Christoph Lübbert, Justyna Siwy, Goce Spasovski, Andrzej Wiecek, Heiko von der Leyen, Mimoza Milenkova, Julia Raad, Aleksandra Canevska-Talevska, Björn Peters, Harald Mischak, Sven Kalbitz, Matthias Schwab, and Ralph Wendt
- Subjects
medicine.medical_specialty ,Urinary system ,Logistic regression ,01 natural sciences ,03 medical and health sciences ,0302 clinical medicine ,Urinary proteomics ,Internal medicine ,Medicine ,030212 general & internal medicine ,0101 mathematics ,Disease severity ,Framingham Risk Score ,Receiver operating characteristic ,business.industry ,SARS-CoV-2 ,010102 general mathematics ,Area under the curve ,COVID-19 ,General Medicine ,Odds ratio ,Biomarker (medicine) ,Risk score ,business ,Body mass index ,Research Paper - Abstract
BACKGROUND: COVID-19 prediction models based on clinical characteristics, routine biochemistry and imaging, have been developed, but little is known on proteomic markers reflecting the molecular pathophysiology of disease progression. METHODS: The multicentre (six European study sites) Prospective Validation of a Proteomic Urine Test for Early and Accurate Prognosis of Critical Course Complications in Patients with SARS-CoV-2 Infection Study (Crit-COV-U) is recruiting consecutive patients (≥ 18 years) with PCR-confirmed SARS-CoV-2 infection. A urinary proteomic biomarker (COV50) developed by capillary-electrophoresis-mass spectrometry (CE-MS) technology, comprising 50 sequenced peptides and identifying the parental proteins, was evaluated in 228 patients (derivation cohort) with replication in 99 patients (validation cohort). Death and progression along the World Health Organization (WHO) Clinical Progression Scale were assessed up to 21 days after the initial PCR test. Statistical methods included logistic regression, receiver operating curve (ROC) analysis and comparison of the area under the curve (AUC). FINDINGS: In the derivation cohort, 23 patients died, and 48 developed worse WHO scores. The odds ratios (OR) for death per 1 standard deviation (SD) increment in COV50 were 3·52 (95% CI, 2·02-6·13, p
- Published
- 2021
18. Usefulness of lactate albumin ratio at admission to predict 28-day mortality in critically ill severely burned patients: A retrospective cohort study
- Author
-
Emmanuel Dudoignon, Thomas Quennesson, Christian De Tymowski, Nabila Moreno, Maxime Coutrot, Maïté Chaussard, Lucie Guillemet, Sonia Abid, Alexandre Fratani, Quentin Ressaire, Alexandru Cupaciu, Vagh Weinmann, Alexandre Pharaboz, Mourad Benyamina, Alexandre Mebazaa, Matthieu Legrand, François Depret, and Benjamin Deniau
- Subjects
Male ,Critical Illness ,Albumins ,Emergency Medicine ,Humans ,Surgery ,General Medicine ,Lactic Acid ,Critical Care and Intensive Care Medicine ,Burns ,Prognosis ,Retrospective Studies - Abstract
Lactate albumin ratio (LAR) has been used as a prognostic marker associated with organ failure in critically ill septic patients. LAR and its association with outcomes has never been studied in burned patients. The aim of this study was to evaluate the ability of LAR to predict 28-day mortality.A retrospective cohort study including all burn patients hospitalized in intensive care unit. The primary endpoint was the 28-day mortality.One thousand three hundred thirty four patients were screened, and 471 were included between June 2012 and December 2018. Briefly, the population study was mainly composed by men (249, 59.1%), the median age, TBSA burned, full thickness, ABSI and IGS2 were 52 [34-68], 20 [10-40], 8 [1-23], 7 [5-9] and 25 [15-40] respectively. Fifty-two patients (12.4%) died at day 28 after admission. At admission, the LAR level was lower in 28-day survivors compared non-survivors (0.05 [0.04, 0.08] vs 0.12 [0.07, 0.26], p 0.001 respectively). In multivariate analysis accounting for ABSI, LAR levels at admission 0.13 was independently associated with 28-day mortality (adjusted OR = 3.98 (IC95 1.88-8.35)). The ability of LAR at admission to discriminate 28-day mortality showed an AUC identical when compared to SOFA and ABSI scores (0.81 (IC95 0.74-0.88), 0.80 (IC95 0.72-0.85) and (0.85 (IC95 0.80-0.90), p 0.05, respectively). Patients with LAR levels ≥ 0.13 at admission had higher 28-day mortality (40.6% vs 6.8%, p 0.001, HR 7.39 (IC95 4.28-12.76)).At admission, LAR is an easy and reliable marker independently associated to 28-day mortality in patients with severe burn injury, but prediction by LAR does not perform better than lactate level alone.
- Published
- 2021
19. Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort
- Author
-
Sofiane Fodil, Magalie Collet, Benoit Plaud, Pierre-Antoine Oillic, Emmanuel Dudoignon, Bruno Mégarbane, Elie Azoulay, Stéphane Bretagne, Théo Ghelfenstein-Ferreira, Sarah Dellière, François Dépret, Sebastian Voicu, Alexandre Mebazaa, Benjamin G. Chousterman, Alexandre Alanio, Maud Salmona, Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals (CNRMA), Institut Pasteur [Paris], Hopital Saint-Louis [AP-HP] (AP-HP), Service de Réanimation Médicale et Toxicologique [Hôpital Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Hôpital Lariboisière-Fernand-Widal [APHP], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Université Sorbonne Paris Nord, Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], No external funding was received for the present study, We thank Dr Pierre Gazeau for providing follow-up information regarding patients transferred to Brest University Hospital. We thank all staff, nurses, lab technicians who were essential to patients care in intensive care and medical mycology from Saint Louis Hospital and Lariboisière Hospital., Institut Pasteur [Paris] (IP), Optimisation thérapeutique en Neuropsychopharmacologie (OPTeN (UMR_S_1144 / U1144)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Génomique évolutive, modélisation et santé (GEMS), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), and Alanio, Alexandre
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,030106 microbiology ,Azithromycin ,[SDV.BID.SPT]Life Sciences [q-bio]/Biodiversity/Systematics, Phylogenetics and taxonomy ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Internal medicine ,[SDV.BID.SPT] Life Sciences [q-bio]/Biodiversity/Systematics, Phylogenetics and taxonomy ,Medicine ,Corticosteroids ,Medical history ,030212 general & internal medicine ,skin and connective tissue diseases ,[SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology ,azithromycin ,business.industry ,SARS-CoV-2 ,Incidence (epidemiology) ,COVID-19 ,Retrospective cohort study ,Odds ratio ,General Medicine ,bacterial infections and mycoses ,Intensive care unit ,[SDV.MP.MYC] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology ,Confidence interval ,3. Good health ,respiratory tract diseases ,Coronavirus ,Research Note ,Critical care ,Aspergillus ,Infectious Diseases ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Complication ,business ,medicine.drug - Abstract
Objectives The main objective of this study was to determine the incidence of invasive pulmonary aspergillosis (IPA) in patients with coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU), and to describe the patient characteristics associated with IPA occurrence and to evaluate its impact on prognosis. Methods We conducted a retrospective cohort study including all successive COVID-19 patients, hospitalized in four ICUs, with secondary deterioration and one or more respiratory samples sent to the mycology department. We used a strengthened IPA testing strategy including seven mycological criteria. Patients were classified as probable IPA according to the European Organization for Research and Treatment of Cancer (EORTC)/Mycoses Study Group Education and Research Consortium (MSGERC) classification if immunocompromised, and according to the recent COVID-19-associated IPA classification otherwise. Results Probable IPA was diagnosed in 21 out of the 366 COVID-19 patients (5.7%) admitted to the ICU and in the 108 patients (19.4%) who underwent respiratory sampling for deterioration. No significant differences were observed between patients with and without IPA regarding age, gender, medical history and severity on admission and during hospitalization. Treatment with azithromycin for ≥3 days was associated with the diagnosis of probable IPA (odds ratio 3.1, 95% confidence interval 1.1–8.5, p=0.02). A trend was observed with high-dose dexamethasone and the occurrence of IPA. Overall mortality was higher in the IPA patients (15/21, 71.4% versus 32/87, 36.8%, p Conclusion IPA is a relatively frequent complication in severe COVID-19 patients and is responsible for increased mortality. Azithromycin, known to have immunomodulatory properties, may contribute to increase COVID-19 patient's susceptibility to IPA.
- Published
- 2021
- Full Text
- View/download PDF
20. Is the Renin-Angiotensin-Aldosterone System Good for the Kidney in Acute Settings?
- Author
-
Emmanuel Dudoignon, François Dépret, and Matthieu Legrand
- Subjects
medicine.medical_specialty ,030232 urology & nephrology ,Angiotensin-Converting Enzyme Inhibitors ,030204 cardiovascular system & hematology ,Kidney ,Renin-Angiotensin System ,Contractility ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Renin–angiotensin system ,Angiotensin-2 ,Renal fibrosis ,medicine ,Animals ,Humans ,Mineralocorticoid Receptor Antagonists ,business.industry ,Acute kidney injury ,Renal inflammation ,Acute Kidney Injury ,medicine.disease ,Fibrosis ,medicine.anatomical_structure ,Blood pressure ,Cardiology ,business - Abstract
The renin-angiotensin-aldosterone system (RAAS) plays a major role in the regulation of blood pressure, renal hemodynamic, myocardial contractility via an enzymatic cascade leading to the synthesis of angiotensin 2. The activation of the RAAS system after acute kidney injury triggers renal inflammation and fibrotic process with long-term damaging consequences. To date, there is still a debate on the benefits of RAAS for the kidney in acute settings. Effects of RAAS antagonists are variable in chronic or acute conditions. The aim of this review is to discuss the renal and systemic effects of the RAAS, and its modulation, in acute situations.
- Published
- 2019
21. Outcome and potentially modifiable risk factors for candidemia in critically ill burns patients: A matched cohort study
- Author
-
Blandine Denis, Marc Chaouat, Alexandre Alanio, Christian de Tymowski, Alexandru Cupaciu, David Boccara, François Dépret, Stéphane Bretagne, Haikel Oueslati, Maurice Mimoun, Axelle Ferry, Sabri Soussi, Matthieu Lafaurie, Maud Gits-Muselli, Emmanuel Dudoignon, Maxime Coutrot, Alexandre Fratani, James Anstey, Kevin Serror, Marion Jully, Matthieu Legrand, Maïté Chaussard, Mourad Benyamina, and Alexandre Mebazaa
- Subjects
Adult ,Male ,0301 basic medicine ,Antifungal ,medicine.medical_specialty ,medicine.drug_class ,Critical Illness ,030106 microbiology ,Dermatology ,Sepsis ,030207 dermatology & venereal diseases ,03 medical and health sciences ,fluids and secretions ,0302 clinical medicine ,Matched cohort ,Risk Factors ,hemic and lymphatic diseases ,Antibiotic therapy ,Internal medicine ,medicine ,Humans ,Aged ,Retrospective Studies ,Icu mortality ,Critically ill ,Septic shock ,business.industry ,Candidemia ,General Medicine ,Middle Aged ,equipment and supplies ,bacterial infections and mycoses ,medicine.disease ,Survival Analysis ,Drug Utilization ,Anti-Bacterial Agents ,Treatment Outcome ,Infectious Diseases ,Candida spp ,Female ,Burns ,business - Abstract
BACKGROUND Patients with extensive burns are at risk of developing candidemia. OBJECTIVES To identify potentially modifiable risk factors and outcomes of candidemia in critically ill burns patients. PATIENTS AND METHODS Retrospective matched cohort study including adult burns patients. Patients who developed candidemia were matched with burns patients with Candida spp colonisation and sepsis or septic shock without candidemia in a ratio of 1:3 (same severity scores and colonisation index). Univariate and multiple regression analyses were performed. RESULTS Of 130 severely burned patients with Candida spp colonisation and at least one episode of sepsis or septic shock, 14 were diagnosed with candidemia. In the candidemia group, patients had a median (IQR) total burns surface area (TBSA) of 57 (38-68)%, SAPSII of 43 (36-58) and ABSI of 11 (8-13). Multiple regression analysis showed that only duration of prior antibiotic therapy was independently associated with candidemia. ICU mortality was higher in the candidemia group (71% vs 35% [P = 0.02]). The log-rank test for 28-day mortality comparing patients with candidemia treated with an empirical strategy vs a curative strategy did not reach significance (P = 0.056). CONCLUSIONS Burns patients having received recent antibiotherapy have a higher risk of candidemia. Antifungal strategies did not influence outcome in this series.
- Published
- 2018
22. Performance of a multiplex polymerase chain reaction panel for identifying bacterial pathogens causing pneumonia in critically ill patients with COVID-19
- Author
-
Thibaut Poncin, Béatrice Berçot, Mourad Benyamina, Alexandre Mebazaa, François Caméléna, Jérôme Le Goff, Benoit Plaud, Emmanuel Dudoignon, Anne Clotilde Moy, Lucie Guillemet, Matthieu Lafaurie, Maxime Coutrot, Maïté Chaussard, Mélissa Budoo, François Dépret, Benjamin Deniau, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), CCSD, Accord Elsevier, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Université Sorbonne Paris Nord
- Subjects
Male ,0301 basic medicine ,Microbiology (medical) ,Time Factors ,Microbiological culture ,Critical Illness ,[SDV]Life Sciences [q-bio] ,030106 microbiology ,medicine.disease_cause ,Sensitivity and Specificity ,Article ,Microbiology ,03 medical and health sciences ,0302 clinical medicine ,Multiplex polymerase chain reaction ,Pneumonia, Bacterial ,medicine ,Humans ,030212 general & internal medicine ,Pathogen ,Aged ,Bacteriological Techniques ,Bacteria ,medicine.diagnostic_test ,Pseudomonas aeruginosa ,business.industry ,SARS-CoV-2 ,Bacterial pneumonia ,COVID-19 ,General Medicine ,Rapid diagnostics ,Middle Aged ,medicine.disease ,3. Good health ,[SDV] Life Sciences [q-bio] ,Pneumonia ,Infectious Diseases ,Bronchoalveolar lavage ,Staphylococcus aureus ,Female ,business ,Bronchoalveolar Lavage Fluid ,Multiplex Polymerase Chain Reaction ,FilmArray Pneumonia Plus - Abstract
International audience; The FilmArray® Pneumonia Plus (FA-PP) panel can provide rapid identifications and semiquantitative results for many pathogens. We performed a prospective single-center study in 43 critically ill patients with coronavirus disease 2019 (COVID-19) in which we performed 96 FA-PP tests and cultures of blind bronchoalveolar lavage (BBAL). FA-PP detected 1 or more pathogens in 32% (31/96 of samples), whereas culture methods detected at least 1 pathogen in 35% (34/96 of samples). The most prevalent bacteria detected were Pseudomonas aeruginosa (n = 14) and Staphylococcus aureus (n = 11) on both FA-PP and culture. The FA-PP results from BBAL in critically ill patients with COVID-19 were consistent with bacterial culture findings for bacteria present in the FA-PP panel, showing sensitivity, specificity, and positive and negative predictive value of 95%, 99%, 82%, and 100%, respectively. Median turnaround time for FA-PP was 5.5 h, which was significantly shorter than for standard culture (26 h) and antimicrobial susceptibility testing results (57 h).
- Published
- 2021
23. Sleep is not an option: Reply to Robin et al
- Author
-
Colleen Breslin, François Dépret, Benoit Plaud, and Emmanuel Dudoignon
- Subjects
medicine.medical_specialty ,business.industry ,Polysomnography ,General Medicine ,Critical Care and Intensive Care Medicine ,Sleep in non-human animals ,Songbirds ,Anesthesiology and Pain Medicine ,Medicine ,Animals ,Humans ,business ,Psychiatry ,Sleep - Published
- 2021
24. Perfusion Index: Physical Principles, Physiological Meanings and Clinical Implications in Anaesthesia and Critical Care
- Author
-
Jona Joachim, Emmanuel Dudoignon, Etienne Gayat, Fabrice Vallée, François Dépret, Maxime Coutrot, Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Paris (UP), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Université Sorbonne Paris Nord, Laboratoire de mécanique des solides (LMS), École polytechnique (X)-MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS), Mathematical and Mechanical Modeling with Data Interaction in Simulations for Medicine (M3DISIM), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École polytechnique (X)-MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Inria Saclay - Ile de France, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], Université Paris Cité (UPCité), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, École polytechnique (X)-Mines Paris - PSL (École nationale supérieure des mines de Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École polytechnique (X)-Mines Paris - PSL (École nationale supérieure des mines de Paris), and Zunara, Fatima
- Subjects
Light absorbance ,Critical Care ,Perfusion index ,Haemodynamic monitoring ,Neuraxial blockade ,Critical Care and Intensive Care Medicine ,03 medical and health sciences ,0302 clinical medicine ,030202 anesthesiology ,Photoplethysmogram ,Intensive care ,Humans ,Medicine ,Anesthesia ,Oximetry ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,business.industry ,Signal Processing, Computer-Assisted ,030208 emergency & critical care medicine ,General Medicine ,Perioperative ,3. Good health ,Anesthesiology and Pain Medicine ,non-invasive monitoring ,Narrative review ,photoplethysmography ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Short title: Clinical Usefulness of Perfusion Index; International audience; Photoplethysmography (PPG) has been extensively used for pulse oximetry monitoring in anaesthesia, perioperative and intensive care. However, some components of PPG signal have been employed for other purposes, such as non-invasive haemodynamic monitoring. Perfusion index (PI) is derived from PPG signal and represents the ratio of pulsatile on non-pulsatile light absorbance or reflectance of the PPG signal. PI determinants are complex and interlinked, involving and reflecting the interaction between peripheral and central haemodynamic characteristics, such as vascular tone and stroke volume. Recently, several studies have shed light on the interesting performances of this variable, especially assessing regional or neuraxial block success, and haemodynamic monitoring in anaesthesia, perioperative and intensive care. Nevertheless, no review has yet been published concerning the interest of PI in these fields. In this narrative review will be exposed first the physiological and pathophysiological determinants of PI, and then the mean to measure this value as well as its potential limitations. In the second part, the existing data concerning usefulness of PI in different clinical settings such as operating theatres, intensive care units and emergency departments will be presented and discussed. Finally, the perspectives concerning the use of PI and mentioned aspects that should be explored regarding this tool will be underlined.
- Published
- 2021
25. Ketamine-induced cholangiopathy in ARDS patients
- Author
-
François Dépret, Matthieu Legrand, Christian de Tymowski, Vincent Mallet, and Emmanuel Dudoignon
- Subjects
medicine.medical_specialty ,ARDS ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Pain medicine ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,MEDLINE ,Critical Care and Intensive Care Medicine ,medicine.disease ,Anesthesiology ,Emergency medicine ,medicine ,Ketamine ,business ,medicine.drug - Published
- 2021
26. Intravenous ketamine and progressive cholangiopathy in COVID-19 patients
- Author
-
Vincent Mallet, Kilian Bock, Paul Doumbe Mandengue, Nicolas Dufour, Torsten Voigtlaender, Jean-Damien Ricard, Pierre Isnard, Vincent Frochot, Emmanuel Letavernier, Lucile Moga, Amandine Landrieux, Pierre-Emmanuel Rautou, Nathalie Pons-Kerjean, Anaïs Vallet-Pichard, Laurent Chouchana, Coralie Gernez, Carole Burger, Anne Scemla, Christian de Tymoski, François Depret, Emmanuel Dudoignon, Lionel Lamhaut, Rémi Flicoteau, Géraldine Rousseau, Jean-Paul Duong Van Huyen, Jean-Michel Correas, Heiner Wedemeyer, and Stanislas Pol
- Subjects
Male ,Cholangiopathy ,2019-20 coronavirus outbreak ,Intravenous ketamine ,Coronavirus disease 2019 (COVID-19) ,Cholangitis ,Biopsy ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Covid-19, Coronavirus infectious disease 2019 ,Bile Duct Diseases ,AST, aspartate aminotransferase ,UDCA, ursodeoxycholic acid ,End Stage Liver Disease ,ULN, upper limit of normal ,Liver Function Tests ,Cholestasis ,Germany ,ALT, alanine aminotransferase ,medicine ,Humans ,GGT, gamma-glutamyl transferase ,Ketamine ,Letter to the Editor ,Intrahepatic ,Anesthetics, Dissociative ,Duration of Therapy ,Dose-Response Relationship, Drug ,ALP, alkaline phosphatase ,Hepatology ,SARS-CoV-2 ,business.industry ,Middle Aged ,medicine.disease ,Respiration, Artificial ,Outcome and Process Assessment, Health Care ,Anesthesia ,Administration, Intravenous ,Female ,France ,Drug Monitoring ,Chemical and Drug Induced Liver Injury ,Covid-19 ,business ,MRI, magnetic resonance imaging ,medicine.drug - Published
- 2021
27. Three-month quality of life in survivors of ARDS due to COVID-19: a preliminary report from a French academic centre
- Author
-
Emmanuel Dudoignon, Quentin Ressaire, Benoit Plaud, François Dépret, and Arnaud Valent
- Subjects
medicine.medical_specialty ,2019-20 coronavirus outbreak ,ARDS ,post-intensive care syndrome ,Coronavirus disease 2019 (COVID-19) ,Critical Care and Intensive Care Medicine ,Quality of life (healthcare) ,Preliminary report ,Pandemic ,medicine ,Humans ,Survivors ,Letter to the Editor ,Fatigue ,Respiratory Distress Syndrome ,business.industry ,SARS-CoV-2 ,COVID-19 ,Retrospective cohort study ,General Medicine ,medicine.disease ,Post-intensive care syndrome ,Anesthesiology and Pain Medicine ,quality of life ,Emergency medicine ,business - Published
- 2020
28. Low total cholesterol blood level is correlated with pulmonary severity in COVID-19 critical ill patients
- Author
-
Nabila Moreno, Maxime Coutrot, François Dépret, Quentin Ressaire, and Emmanuel Dudoignon
- Subjects
Blood level ,Male ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Critical Illness ,Critical Care and Intensive Care Medicine ,Severity of Illness Index ,chemistry.chemical_compound ,Internal medicine ,Severity of illness ,medicine ,Low total cholesterol ,Humans ,Letter to the Editor ,Apolipoproteins A ,Triglycerides ,Aged ,Apolipoproteins B ,Retrospective Studies ,business.industry ,Cholesterol ,SARS-CoV-2 ,Cholesterol, HDL ,COVID-19 ,Retrospective cohort study ,General Medicine ,Cholesterol, LDL ,Middle Aged ,Anesthesiology and Pain Medicine ,chemistry ,Female ,business ,Respiratory Insufficiency - Published
- 2020
29. Bacterial Pneumonia in COVID-19 Critically Ill Patients: A Case Series
- Author
-
François Dépret, Emmanuel Dudoignon, Adrien Habay, Béatrice Berçot, Benjamin Deniau, Quentin Ressaire, Benoit Plaud, Maxime Coutrot, and François Caméléna
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Critically ill ,business.industry ,Coinfection ,SARS-CoV-2 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Critical Illness ,Bacterial pneumonia ,COVID-19 ,medicine.disease ,Coronavirus ,Pneumonia ,AcademicSubjects/MED00290 ,Infectious Diseases ,Anti-Infective Agents ,Correspondence ,Critical illness ,medicine ,Pneumonia, Bacterial ,Humans ,Intensive care medicine ,business - Published
- 2020
30. Ketamine for maintenance sedation in critically ill burned patients is associated with liver dysfunction and acute kidney injury
- Author
-
Christian de Tymowski, Emmanuel Dudoignon, Nabila Moreno, Francois Depret, Matthieu Legrand, Alexandre Mebazaa, and Vincent Mallet
- Subjects
Hepatology - Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.